domingo, 22 de septiembre de 2013

The Cost-Effectiveness of Maturity-Onset Diabe... [Diabetes Care. 2013] - PubMed - NCBI

Public Health Sciences

a globe surrounded by computer monitors with images of people with are connected to each other
The cost-effectiveness of maturity-onset diabetes of the young genetic testing - translating genomic advances into practical health applicationsExternal Web Site Icon
Naylor RN, et al. Diabetes Care 2013 Sep
The establishment of core competencies for Canadian genetic counsellors: Validation of practice based competenciesExternal Web Site Icon
Ferrier RA, et al. J Genet Couns 2013 Sep
Genetic susceptible locus in NOTCH2 interacts with arsenic in drinking water on risk of Type 2 Diabetes.External Web Site Icon
Pan WC, et al. PLoS One. 2013 Aug 14;8(8):e70792
Genome-wide association analysis of blood-pressure traits in African-ancestry individuals reveals common associated genes in African and non-African populations.External Web Site Icon
Franceschini N, et al. Am J Hum Genet. 2013 Sep 5;93(3):545-54.
Genotype- and phenotype-directed personalization of antiplatelet treatment in patients with non-ST elevation acute coronary syndromes undergoing coronary stentingExternal Web Site Icon
Ahn SG, et al. Korean Circ J 2013 Aug;43(8):541-9
A host-based RT-PCR gene expression signature to identify acute respiratory viral infectionExternal Web Site Icon
Zaas A, et al. Sci Transl Med 5(203):203ra126 2013 Sep 18
Population-based carrier screening for cystic fibrosis: a systematic review of 23 years of researchExternal Web Site Icon
Ioannou L, et al. Genet Med 2013 Sep
Reproducibility of high-throughput mRNA and small RNA sequencing across laboratories.External Web Site Icon
Peter A C 't Hoen et al. Nature Biotechnology, September 15
The return of unexpected research results in a biobank study and referral to health care for heritable Long QT syndromeExternal Web Site Icon
Haukkala A, et al. Public Health Genomics 2013 Sep:241-50
Stakeholder engagement: a key component of integrating genomic information into electronic health recordsExternal Web Site Icon
Hartzler A, et al. Genet Med 2013 Sep

The Cost-Effectiveness of Maturity-Onset Diabe... [Diabetes Care. 2013] - PubMed - NCBI
Diabetes Care. 2013 Sep 11. [Epub ahead of print]

The Cost-Effectiveness of Maturity-Onset Diabetes of the Young Genetic Testing - Translating Genomic Advances into Practical Health Applications.


Department of Pediatrics, Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, University of Chicago, Chicago, Illinois;


ObjectiveTo evaluate the cost-effectiveness of a genetic testing policy for HNF1A, HNF4A and GCK-MODY in a hypothetical cohort of type 2 diabetes patients 25-40 years old with a MODY prevalence of 2%.Research Design and MethodsWe used a simulation model of type 2 diabetes complications based on UKPDS data, modified to account for the natural history of disease by genetic subtype, to compare a policy of genetic testing at diabetes diagnosis versus a policy of no testing. Under the screening policy, successful sulfonylurea treatment of HNF1A-MODY and HNF4A-MODY was modeled to produce a glycosylated hemoglobin reduction of -1.5%, compared to usual care. GCK-MODY received no therapy. Main outcome measures were costs and quality-adjusted life years (QALYs), based on lifetime risk of complications and treatments, expressed as the incremental cost-effectiveness ratio (ICER, $/QALY).ResultsThe testing policy yielded an average gain of 0.012 QALYs and resulted in an ICER of $205,000. Sensitivity analysis showed that if the MODY prevalence was 6%, the ICER would be ∼$50,000. If MODY prevalence was >30%, the testing policy was cost-saving. Reducing genetic testing costs to $700 also resulted in an ICER of ∼$50,000.ConclusionsOur simulated model suggests a policy of testing for MODY in selected populations is cost-effective for the United States based on contemporary ICER thresholds. Higher prevalence of MODY in the tested population or decreased testing costs would enhance cost-effectiveness. Our results make a compelling argument for routine coverage of genetic testing in patients with high clinical suspicion of MODY.
[PubMed - as supplied by publisher]

No hay comentarios: